Lineage Cell Therapeutics reports Q3 net loss of $6.1M; appoints Jill Howe as CFO

Lineage Cell Therapeutics, Inc.

2022-Q3 EPS reported -$0.12 revenue$12,788,000

Net loss attributable to Lineage of $6.1M ($0.04/share) vs $7.8M ($0.05/share) in Q3 2021.
Total revenue $3.0M, up from $2.3M YoY, driven by Roche collaboration revenue.
Cash, equivalents, and marketable securities $66.4M as of Sep 30, 2022; expected runway into Q3 2024.
Appointed Jill Howe as CFO effective Nov 14, 2022; she has 20+ years biotech finance experience.
Received notice of allowance for two patents covering directed differentiation methods for RPE and OPC cells.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lineage Cell Therapeutics, Inc. reported the third quarter of 2022 results: revenue approximately $3.0 million.

Period: the third quarter of 2022
Revenue: approximately $3.0 million
Result: reported results

Exact text from the filing

generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues for the three months ended September 30, 2022 were approximately $3.0 million, a net increase of $0.7 million as compared to $2.3 million for the same period in 2021. The increase was driven by collaboration and licensing revenue recognized from deferred

View on SEC.gov

Browse all earnings releases →

Lineage Cell Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-031351

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.